Phase I single-group intervention (n=30) evaluating enhanced psilocybin microdosing (0.15–0.33 g dosing; monthly 1–1.5 g maintenance) for chronic conditions including PTSD, chronic depression, MS, HIV and Long COVID.
This single-group Phase I study evaluates a tailored enhanced microdosing regimen of non-synthetic psilocybin delivered orally to participants with chronic illness (including PTSD, chronic depression, MS, HIV and SARS-CoV-2 long-haul syndrome) over an eight-week course with monthly maintenance dosing.
Participants are onboarded and monitored by a multidisciplinary team (psychiatrist, LCPC therapist, Plant Medicine On-Boarding Provider) who will tailor dosing and manage reduction of concurrent SSRIs where clinically appropriate; outcomes include feasibility, safety, and measures of symptom change and quality of life.
Tailored enhanced microdosing schedule with monthly maintenance dose; single-group treatment protocol.
Enhanced microdosing 0.15–0.33 g (typical up to 0.33 g); monthly single maintenance dose 1–1.5 g; dose tailored by PMOP/psychiatrist.